With its five-months-early FDA approval for Trikafta, Vertex ushered in the triple combo era in cystic fibrosis—and majorly expanded its treatable population in the process.
Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.
